Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
127 hedge funds and large institutions have $818M invested in Intra-Cellular Therapies Inc. in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 61 increasing their positions, 32 reducing their positions, and 23 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 32
4% less funds holding
Funds holding: 132 → 127 (-5)
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
47% less capital invested
Capital invested by funds: $1.53B → $818M (-$716M)
52% less call options, than puts
Call options by funds: $5M | Put options by funds: $10.4M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$11.7M |
| 2 |
O
OrbiMed
New York
|
+$9.8M |
| 3 |
Millennium Management
New York
|
+$9.51M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$6.86M |
| 5 |
Renaissance Technologies
New York
|
+$6.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$18.9M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$6.63M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$5.59M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$4.13M |
| 5 |
VAM
Visium Asset Management
New York
|
-$4.11M |
ITCI Hedge Fund Activity: Q1 2016 in Review
127 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2016, worth a combined $818M — down 47% from $1.53B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ITCI and 19 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 61 added.
The largest buyer was EverPoint Asset Management, adding an estimated $11.7M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $18.9M sold.
- 127 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2016, down from 132 in Q4 2015.
- Funds reported $818M of Intra-Cellular Therapies Inc. stock for Q1 2016, down 47% quarter-over-quarter.
- 19 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2016 and 23 closed out, a net change of -4 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q1 2016 was EverPoint Asset Management, an estimated $11.7M added.
- The largest Intra-Cellular Therapies Inc. seller in Q1 2016 was Loomis, Sayles & Company, an estimated $18.9M sold.
Based on aggregated 13F filings for Q1 2016.